Payment overview · 2025
General Payments
$1,802.84
107 reported records · 27 companies
Healthcare provider profile · identity verified
Wallace C Baker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · IDAHO FALLS, ID · NPI 1083696967
Verified facts
What the public records show
CMS Open Payments records show Wallace C Baker, M.D. received $1,802.84 in general payments during 2025 across 107 reported records.
ABBVIE INC. accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Veozah, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Enbrel by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Veozah by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 426 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 426 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $241.67 | 13.4% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.77 | 8.6% | 14 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $153.12 | 8.5% | 9 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $145.64 | 8.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $141.97 | 7.9% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $133.47 | 7.4% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $105.59 | 5.9% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $89.55 | 5.0% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $70.89 | 3.9% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $69.88 | 3.9% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$65.63 | 3.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.18 | 3.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.75 | 3.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.56 | 3.0% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $46.14 | 2.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.72 | 1.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.80 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.96 | 1.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.56 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.17 | 1.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.98 | 1.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.44 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.98 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.35 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.26 | 0.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.23 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.58 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,802.84 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $166.61 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $162.77 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $153.12 | 9 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $145.64 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.97 | 7 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $111.87 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $102.78 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $94.87 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $89.55 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $89.53 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.06 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $70.89 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $69.88 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.90 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.28 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.75 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $46.14 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 426 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 124 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
141 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
426 | 53 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
60 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
72 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
92 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
124 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
426 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 607 | 128 |
| Eliquis | Apixaban | 426 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 86 |
| Potassium Chloride | Potassium Chloride | 332 | 58 |
| Omeprazole | Omeprazole | 321 | 92 |
| Furosemide | Furosemide | 285 | 59 |
| Losartan Potassium | Losartan Potassium | 267 | 66 |
| Gabapentin | Gabapentin | 262 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 49 |
| Lisinopril | Lisinopril | 189 | 57 |
| Metformin Hcl | Metformin Hcl | 186 | 38 |
| Carvedilol | Carvedilol | 170 | 40 |
| Simvastatin | Simvastatin | 169 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 156 | 30 |
| Allopurinol | Allopurinol | 155 | 39 |
| Myrbetriq | Mirabegron | 141 | 16 |
| Estradiol | Estradiol | 136 | 28 |
| Trazodone Hcl | Trazodone Hcl | 135 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 39 |
| Montelukast Sodium | Montelukast Sodium | 128 | 30 |
| Metformin Hcl Er | Metformin Hcl | 125 | 34 |
| Famotidine | Famotidine | 124 | 38 |
| Mounjaro | Tirzepatide | 124 | 23 |
| Donepezil Hcl | Donepezil Hcl | 112 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 33 |
| Celecoxib | Celecoxib | 106 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 14 |
| Sertraline Hcl | Sertraline Hcl | 99 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 14 |
| Meloxicam | Meloxicam | 96 | 29 |
| Xarelto | Rivaroxaban | 92 | 12 |
| Jardiance | Empagliflozin | 91 | suppressed |
| Bupropion Xl | Bupropion Hcl | 90 | 25 |
| Farxiga | Dapagliflozin Propanediol | 90 | 14 |
| Clonidine Hcl | Clonidine Hcl | 87 | 17 |
| Movantik | Naloxegol Oxalate | 87 | suppressed |
| Baclofen | Baclofen | 85 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 31 |
| Lamotrigine | Lamotrigine | 82 | suppressed |
| Prednisone | Prednisone | 82 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 30 |
| Tramadol Hcl | Tramadol Hcl | 76 | 23 |
| Memantine Hcl | Memantine Hcl | 75 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 24 |
| Topiramate | Topiramate | 75 | 13 |
| Levetiracetam | Levetiracetam | 74 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 72 | 62 |
| Ibuprofen | Ibuprofen | 69 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 13 |
| Spironolactone | Spironolactone | 66 | 22 |
| Minocycline Hcl | Minocycline Hcl | 64 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | suppressed |
| Ozempic | Semaglutide | 61 | 20 |
| Rexulti | Brexpiprazole | 61 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 60 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | 12 |
| Clonazepam | Clonazepam | 56 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Linzess | Linaclotide | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 12 |
| Carbamazepine | Carbamazepine | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | 17 |
| Diazepam | Diazepam | 42 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Torsemide | Torsemide | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | 13 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Latanoprost | Latanoprost | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 32 | 32 |
| Colesevelam Hcl | Colesevelam Hcl | 32 | 14 |
| Fluconazole | Fluconazole | 32 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 21 |
| Finasteride | Finasteride | 31 | 11 |
| Cephalexin | Cephalexin | 30 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 14 |
| Digoxin | Digoxin | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Zonisamide | Zonisamide | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Lamictal | Lamotrigine | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Rufinamide | Rufinamide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Prevalite | Cholestyramine | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Veozah | Fezolinetant | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Acetazolamide Er | Acetazolamide | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Imiquimod | Imiquimod | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Pentasa | Mesalamine | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Ridaura | Auranofin | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,802.84 · 107 records | ABBVIE INC. | Azstarys, BEYFORTUS, CAPLYTA, CAPVAXIVE, DUPIXENT, ELIQUIS, EVENITY, FANAPT, GARDASIL 9, GVOKE HYPOPEN, General - Pain Management, JARDIANCE, Kerendia, MOUNJARO, NUCALA, NURTEC ODT, OTEZLA, Ozempic, Prolastin-C Liquid, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SPRAVATO, Symbravo, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Veozah, Wegovy, XYOSTED, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error